# Istituto Oncologico Veneto
**Type:** Institutions
**Canonical URL:** https://scholariq.org/institutions/istituto-oncologico-veneto/
## Facts
| Field | Value |
| --- | --- |
| Avg h-index | 81.5 |
| Citations | 636,089 |
| City | Padua |
| Country | IT |
| Description | Istituto Oncologico Veneto is a research organisation in Padua, IT. OpenAlex records 10,138 works and 636,089 citations for it. 1,537 researchers list it as their most recent affiliation. |
| Homepage | http://www.ioveneto.it/index.php |
| OpenAlex ID | https://openalex.org/I4210109345 |
| Researchers | 1,537 |
| ROR ID | https://ror.org/01xcjmy57 |
| Type | healthcare |
| Works | 10,138 |
## University papers
Showing 12 of 15.
- [Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study](https://scholariq.org/papers/nivolumab-in-patients-with-metastatic-dna-mismatch-repair-deficient-or/)
- [Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial](https://scholariq.org/papers/pembrolizumab-in-patients-with-advanced-hepatocellular-carcinoma-previously/)
- [Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer](https://scholariq.org/papers/durable-clinical-benefit-with-nivolumab-plus-ipilimumab-in-dna-mismatch-repair/)
- [Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer](https://scholariq.org/papers/encorafenib-binimetinib-and-cetuximab-in-i-braf-i-v600e-mutated-colorectal/)
- [FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study](https://scholariq.org/papers/folfoxiri-plus-bevacizumab-versus-folfiri-plus-bevacizumab-as-first-line/)
- [Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer](https://scholariq.org/papers/initial-therapy-with-folfoxiri-and-bevacizumab-for-metastatic-colorectal-cancer/)
- [Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/dual-targeted-therapy-with-trastuzumab-and-lapatinib-in-treatment-refractory/)
- [Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study](https://scholariq.org/papers/ramucirumab-versus-placebo-in-combination-with-second-line-folfiri-in-patients/)
- [Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial](https://scholariq.org/papers/primary-tumor-response-to-preoperative-chemoradiation-with-or-without/)
- [The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer](https://scholariq.org/papers/the-keynote-811-trial-of-dual-pd-1-and-her2-blockade-in-her2-positive-gastric/)
- [Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-for-her2/)
- [Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan](https://scholariq.org/papers/rechallenge-for-patients-with-i-ras-i-and-i-braf-i-wild-type-metastatic/)
## University researchers
- [Sara Lonardi](https://scholariq.org/researchers/sara-lonardi/)
## University top topics
Showing 8 of 25.
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.